Loading
In children whose neuroblastoma had come back, adding the anti-GD2 antibody dinutuximab to irinotecan and temozolomide shrank the cancer in half of them, while adding temsirolimus almost never did.
Children's Oncology Group open-label randomised phase 2 selection trial: 35 eligible children with relapsed, refractory or progressive neuroblastoma were randomised to irinotecan and temozolomide with temsirolimus (n 18) or with dinutuximab plus GM-CSF (n 17).
One patient (6 percent) responded with temsirolimus against nine (53 percent, four partial and five complete responses) with dinutuximab. Pain, hypokalaemia, neutropenia, thrombocytopenia, anaemia, fever and hypoxia were the common grade 3 or worse events with dinutuximab; no deaths were attributed to treatment.
Chemo-immunotherapy with dinutuximab became the salvage standard for relapsed neuroblastoma and the regimen to move into first-line induction.
Shares ANBL1221, Dinutuximab (ch14.18) / dinutuximab beta, High-risk neuroblastoma, Irinotecan (and liposomal irinotecan).
Shares ANBL1221, Dinutuximab (ch14.18) / dinutuximab beta, High-risk neuroblastoma, Neuroblastoma (paediatric).
Shares Dinutuximab (ch14.18) / dinutuximab beta, High-risk neuroblastoma, Temozolomide, Neuroblastoma (paediatric).
Shares Dinutuximab (ch14.18) / dinutuximab beta, High-risk neuroblastoma, Neuroblastoma (paediatric).
Shares Dinutuximab (ch14.18) / dinutuximab beta, High-risk neuroblastoma, Neuroblastoma (paediatric).
Shares Dinutuximab (ch14.18) / dinutuximab beta, High-risk neuroblastoma, Neuroblastoma (paediatric).
Shares Dinutuximab (ch14.18) / dinutuximab beta, High-risk neuroblastoma, Neuroblastoma (paediatric).
Shares Dinutuximab (ch14.18) / dinutuximab beta, High-risk neuroblastoma, Neuroblastoma (paediatric).